Physician profile
Benjamin E Devlin-Ruelle
NPI 1598258477
$2,791.57
in general payments reported to CMS, 2019-2025
18 companies · $736 in 2025
The $736 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $250 · 2023: $952 · 2024: $699 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $607.72 | 2021-2025 | Zubsolv |
| Abbvie INC. | $431.08 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $414.86 | 2022-2025 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $238.71 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $220.98 | 2023-2024 | |
| Gilead Sciences, INC. | $216.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.54 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Braeburn INC. | $120.83 | 2023-2025 | Brixadi |
| Lundbeck LLC | $76.77 | 2022-2024 | Rexulti |
| Uswm, LLC | $71.26 | 2021 | |
| Glaxosmithkline, LLC. | $59.87 | 2023-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.43 | 2024-2025 | Caplyta |
| Indivior INC. | $34.51 | 2025 | Sublocade |
| Lilly USA, LLC | $30.22 | 2024-2025 | Mounjaro, Zepbound |
| Actelion Pharmaceuticals US, INC. | $19.84 | 2024 | Opsumit, Uptravi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $17.45 | 2025 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $16.11 | 2022 | |
| Hologic Sales and Service, LLC | $14.10 | 2023 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Devlin-Ruelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.